Company intelligence / Profile preview

Shenzhen Xinqi Pharmaceutical Technology

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Shenzhen Xinqi Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs for metabolic and endocrine disorders. The company is primarily recognized for its development of XQ-101, a novel oral small molecule GLP-1 receptor agonist designed for the treatment of type 2 diabetes and obesity. By leveraging its expertise in medicinal chemistry, Xinqi Pharma aims to provide more convenient and effective oral alternatives to injectable therapies in the metabolic space. The company operates out of Shenzhen's high-tech industrial hubs and maintains a pipeline focused on high-prevalence chronic diseases.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shenzhen Xinqi Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Xinqi Pharmaceutical Technology.

Explore the full profile